ProShare Advisors
HRTX icon

ProShare Advisors’s Heron Therapeutics HRTX Stock Holding History

ProShare Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.93K Sell
20,918
-1,357
-6% -$1.09K ﹤0.01% 1911
2026
Q1 		$17.8K Sell
22,275
-5,800
-21% -$6.72K ﹤0.01% 1841
2025
Q4 		$36.5K Buy
28,075
+1,916
+7% +$2.37K ﹤0.01% 1982
2025
Q3 		$33K Sell
26,159
-5,209
-17% -$8.26K ﹤0.01% 1963
2025
Q2 		$64.9K Buy
31,368
+5,953
+23% +$12.2K ﹤0.01% 1958
2025
Q1 		$55.9K Sell
25,415
-7,648
-23% -$14.8K ﹤0.01% 1939
2024
Q4 		$50.6K Buy
33,063
+10,880
+49% +$17.6K ﹤0.01% 2174
2024
Q3 		$44.1K Buy
22,183
+8,314
+60% +$19.9K ﹤0.01% 1990
2024
Q2 		$48.5K Sell
13,869
-4,735
-25% -$14.5K ﹤0.01% 1753
2024
Q1 		$51.5K Buy
18,604
+1,466
+9% +$3.69K ﹤0.01% 1900
2023
Q4 		$29.1K Buy
17,138
+3,685
+27% +$4.06K ﹤0.01% 1901
2023
Q3 		$13.9K Sell
13,453
-14
-0.1% -$20 ﹤0.01% 1799
2023
Q2 		$15.6K Buy
13,467
+1,355
+11% +$2.42K ﹤0.01% 1842
2023
Q1 		$18.3K Sell
12,112
-1,130
-9% -$2.83K ﹤0.01% 1739
2022
Q4 		$33.1K Buy
13,242
+1,898
+17% +$6.12K ﹤0.01% 1776
2022
Q3 		$48K Sell
11,344
-218
-2% -$853 ﹤0.01% 1663
2022
Q2 		$32K Sell
11,562
-5,762
-33% -$23.1K ﹤0.01% 1746
2022
Q1 		$99K Sell
17,324
-2,822
-14% -$20.7K ﹤0.01% 2035
2021
Q4 		$184K Buy
20,146
+8,308
+70% +$84.8K ﹤0.01% 2063
2021
Q3 		$127K Sell
11,838
-12,130
-51% -$148K ﹤0.01% 1874
2021
Q2 		$372K Buy
23,968
+551
+2% +$8.77K ﹤0.01% 1742
2021
Q1 		$380K Buy
23,417
+4,002
+21% +$71.3K ﹤0.01% 1643
2020
Q4 		$411K Buy
19,415
+8,673
+81% +$151K ﹤0.01% 1393
2020
Q3 		$159K Sell
10,742
-1,168
-10% -$18.2K ﹤0.01% 1455
2020
Q2 		$175K Buy
+11,910
New +$196K ﹤0.01% 1492
2020
Q1 		– Sell
-11,395
Closed -$268K – 1351
2019
Q4 		$268K Buy
+11,395
New +$252K ﹤0.01% 1410
2018
Q4 		– Sell
-8,432
Closed -$267K – 1630
2018
Q3 		$267K Buy
8,432
+28
+0.3% +$1.04K ﹤0.01% 1433
2018
Q2 		$326K Buy
+8,404
New +$268K ﹤0.01% 1333

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

ProShare Advisors's HRTX Position: Q2 2026 in Review

ProShare Advisors reduced its Heron Therapeutics (HRTX) stake by 6.1% in Q2 2026, selling an estimated $1.09K and leaving 20,918 shares worth $8.93K. The position accounts for ﹤0.01% of the portfolio, ranked #1911.

ProShare Advisors first reported a position in HRTX in Q2 2018 and has held it in 28 quarters since. The position peaked at $411K in Q4 2020. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • ProShare Advisors held 20,918 shares of Heron Therapeutics worth $8.93K as of Q2 2026.
  • ProShare Advisors sold 1,357 Heron Therapeutics shares in Q2 2026, an estimated $1.09K.
  • Heron Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1911 holding.
  • ProShare Advisors first reported a position in Heron Therapeutics in Q2 2018 and has held it in 28 quarters since.
  • ProShare Advisors's Heron Therapeutics position peaked at $411K in Q4 2020.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.